MedTech Centauri Therapeutics has received an extra £3.8m in funding from CARB-X to develop its lead antimicrobial drug. The latest cash boost will help move Centauri’s lead ABX-01 candidate into first-in-human clinical trials.  It also takes CARB-X’s investmnt into the company to £9.6m since 2019. Announced in March 2025, the candidate is a broad-spectrum antimicrobial … Continue reading CARB-X takes Centauri funding to £9.6m with latest investment